Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) have been given a consensus recommendation of “Buy” by the eight analysts that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […]
Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the […]
Raymond James analyst Rahul Sarugaser maintained an “Outperform” rating on Fusion Pharmaceuticals in a Tuesday client report, saying the company is breaking new ground in cancer research.